Eltrombopag Added to Standard Immunosuppressive Treatment as Front-Line Therapy for Severe Aplastic Anemia: Long-Term Outcomes of the Phase-3 Randomized Superiority EBMT-SAAWP RACE Study.

Risitano AM, Iacobelli S, Kulasekararaj A, van Os M, Terwel SR, Tuffnell J, Piepenbroek B, Griffin M, Halkes CJM, Recher C, Barraco F, Forcade E, Vallejo JC, Drexler B, Mear JB, Trikha R, Gandhi S, Raiola AM, Daenen LGM, de Groot MR, Daguindau E, Nur E, Barcellini W, Russell NH, Terriou L, Paola Iori A, Barberi W, Sureda A, Sánchez-Ortega I, Xicoy B, Jarque I, Cavenagh J, de Fontbrune FS, Frieri C, Munir T, Tjon JML, Tavitian S, Praire A, Clement L, Rabian F, Marano L, Hill A, Palmisani E, Muus P, Marotta S, Cacace F, Laurino M, Passweg JR, Socié G, Mufti GJ, Dufour C, Peffault de Latour R, Severe Aplastic Anaemia Working Party of the EBMT

Open source

DOI: 10.1002/ajh.70445
Published: 2026 Oct
Container: American journal of hematology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1002/ajh.70445,
  title = {Eltrombopag Added to Standard Immunosuppressive Treatment as Front-Line Therapy for Severe Aplastic Anemia: Long-Term Outcomes of the Phase-3 Randomized Superiority EBMT-SAAWP RACE Study.},
  author = {Risitano AM and Iacobelli S and Kulasekararaj A and van Os M and Terwel SR and Tuffnell J and Piepenbroek B and Griffin M and Halkes CJM and Recher C and Barraco F and Forcade E and Vallejo JC and Drexler B and Mear JB and Trikha R and Gandhi S and Raiola AM and Daenen LGM and de Groot MR and Daguindau E and Nur E and Barcellini W and Russell NH and Terriou L and Paola Iori A and Barberi W and Sureda A and Sánchez-Ortega I and Xicoy B and Jarque I and Cavenagh J and de Fontbrune FS and Frieri C and Munir T and Tjon JML and Tavitian S and Praire A and Clement L and Rabian F and Marano L and Hill A and Palmisani E and Muus P and Marotta S and Cacace F and Laurino M and Passweg JR and Socié G and Mufti GJ and Dufour C and Peffault de Latour R and Severe Aplastic Anaemia Working Party of the EBMT},
  year = {2026},
  journal = {American journal of hematology},
  doi = {10.1002/ajh.70445},
  url = {https://doi.org/10.1002/ajh.70445}
}

RIS

TY  - JOUR
TI  - Eltrombopag Added to Standard Immunosuppressive Treatment as Front-Line Therapy for Severe Aplastic Anemia: Long-Term Outcomes of the Phase-3 Randomized Superiority EBMT-SAAWP RACE Study.
AU  - Risitano AM
AU  - Iacobelli S
AU  - Kulasekararaj A
AU  - van Os M
AU  - Terwel SR
AU  - Tuffnell J
AU  - Piepenbroek B
AU  - Griffin M
AU  - Halkes CJM
AU  - Recher C
AU  - Barraco F
AU  - Forcade E
AU  - Vallejo JC
AU  - Drexler B
AU  - Mear JB
AU  - Trikha R
AU  - Gandhi S
AU  - Raiola AM
AU  - Daenen LGM
AU  - de Groot MR
AU  - Daguindau E
AU  - Nur E
AU  - Barcellini W
AU  - Russell NH
AU  - Terriou L
AU  - Paola Iori A
AU  - Barberi W
AU  - Sureda A
AU  - Sánchez-Ortega I
AU  - Xicoy B
AU  - Jarque I
AU  - Cavenagh J
AU  - de Fontbrune FS
AU  - Frieri C
AU  - Munir T
AU  - Tjon JML
AU  - Tavitian S
AU  - Praire A
AU  - Clement L
AU  - Rabian F
AU  - Marano L
AU  - Hill A
AU  - Palmisani E
AU  - Muus P
AU  - Marotta S
AU  - Cacace F
AU  - Laurino M
AU  - Passweg JR
AU  - Socié G
AU  - Mufti GJ
AU  - Dufour C
AU  - Peffault de Latour R
AU  - Severe Aplastic Anaemia Working Party of the EBMT
PY  - 2026
JO  - American journal of hematology
DO  - 10.1002/ajh.70445
UR  - https://doi.org/10.1002/ajh.70445
ER  -

APA

AM, R., S, I., A, K., M, V. O., SR, T., J, T., B, P., M, G., CJM, H., C, R., F, B., E, F., JC, V., B, D., JB, M., R, T., S, G., AM, R., LGM, D., MR, D. G., E, D., E, N., W, B., NH, R., L, T., A, P. I., W, B., A, S., I, S., B, X., I, J., J, C., FS, D. F., C, F., T, M., JML, T., S, T., A, P., L, C., F, R., L, M., A, H., E, P., P, M., S, M., F, C., M, L., JR, P., G, S., GJ, M., C, D., R, P. D. L., & EBMT, S. A. A. W. P. O. T. (2026). Eltrombopag Added to Standard Immunosuppressive Treatment as Front-Line Therapy for Severe Aplastic Anemia: Long-Term Outcomes of the Phase-3 Randomized Superiority EBMT-SAAWP RACE Study.. American journal of hematology. https://doi.org/10.1002/ajh.70445

Source records

pubmed · retrieved 2026-09-25T06:05:44.740Z
europe-pmc · retrieved 2026-09-25T06:05:44.733Z